Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Iressa (gefitinib)].

Shoji Kudoh1, Akinobu Yoshimura, Akihiko Gemma

  • 1Fourth Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 27, 2003
PubMed
Summary

Gefitinib shows promise for chemotherapy-resistant non-small cell lung cancer but requires further study. More clinical trials are needed to fully evaluate its efficacy and safety, including potential severe adverse events like interstitial lung disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative evaluation of healthcare information provided to patients with thoracic malignancies: patient satisfaction survey of the Japan Lung Cancer Society.

International journal of clinical oncology·2026
Same author

Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study.

Thoracic cancer·2026
Same author

Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.

Cancer science·2026
Same author

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.

Cancer science·2026
Same author

Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study.

JTO clinical and research reports·2026

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, demonstrates activity in chemotherapy-resistant non-small cell lung cancer (NSCLC).
  • While generally well-tolerated, gefitinib carries a risk of severe adverse events, notably interstitial lung disease (ILD) in under 2% of patients.

Purpose of the Study:

  • To assess the clinical utility and safety profile of gefitinib in NSCLC treatment.
  • To identify the need for further clinical evaluation of gefitinib.

Main Methods:

  • Review of existing data on gefitinib efficacy and safety in NSCLC.
  • Identification of data gaps regarding gefitinib's role in various treatment settings.

Main Results:

  • Current data is insufficient for a comprehensive evaluation of gefitinib.
  • Gefitinib exhibits activity but is associated with rare but severe adverse events like ILD.

Conclusions:

  • Further Phase III clinical studies are essential to establish gefitinib's role in second/third-line or maintenance therapy for NSCLC.
  • Individualized therapy approaches may be necessary to optimize gefitinib use and mitigate risks.

Related Experiment Videos